Complement is a circulating system composed of many different proteins which is known for its ability to lyse animal cells and bacteria. This application seeks support for a series of investigations on the effects of complement on that do not lead to lysis of the target cell: the sublytic events. This proposal stems from our observation that when complement is activated at sublytical concentrations, influx of Na and L-glucose into the unlysed erthrocytes increases dramatically, albeit transiently, and yet the affected cells do not lyse or swell, as would be expected. We found that this non-lethal permeability increase is produced by the membrane attack complex, which is a macromolecular complex of the terminal complement components. Further we determined that C8, but not C9, is necessary to produce the sublytic change in permeability and that in response to the sublytic complement attack, there is activation of a Ca-dependent K permeability pathway. This promotes net K efflux and prevents the colloidosmotic swelling and lysis that occurs when the membrane damage is permanent and permits the survival of the affected cell. In PNH, a disease characterized by a dramatic increase in the sensitivity of erythrocytes to complement lysis, there is apparently a lack of sublytic changes for reasons not yet completely understood.
Our specific aims i nclude: 1) continue our studies on the complement regulatory proteins DAF and C8bp, particularly in relation to their role in the sublytic events; 2) characterize further the transient permeability changes and the volume regulatory transport mechanism through studies on ion fluxes during exposure to sublytic complement; and 3) determine the biological consequences of the sublytic events to the cells that survive a complement attack. We will perform studies in normal and PNH erthrocytes, as well as in cells carrying abnormal hemoglobin, such as SS, SC, or CC which are known to have volume regulatory pathways that we predict would decrease their sensitivity to complement lysis. We expect that our investigations will help better understanding complement mediated diseases, such as lupus erythematous and immune hemolytic anemia, and also provide important information on the physiological functions of the complement system and its regulatory proteins.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL033768-10
Application #
2217352
Study Section
Special Emphasis Panel (SSS (G))
Project Start
1989-07-01
Project End
1995-06-30
Budget Start
1993-07-15
Budget End
1995-06-30
Support Year
10
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Tyagi, S; Klickstein, L B; Nicholson-Weller, A (2000) C5a-stimulated human neutrophils use a subset of beta2 integrins to support the adhesion-dependent phase of superoxide production. J Leukoc Biol 68:679-86
Tyagi, S; Nicholson-Weller, A; Barbashov, S F et al. (2000) Intercellular adhesion molecule 1 and beta2 integrins in C1q-stimulated superoxide production by human neutrophils: an example of a general regulatory mechanism governing acute inflammation. Arthritis Rheum 43:2248-59
Wang, C; Bozza, P T; Barbashov, S F et al. (1999) In vitro and in vivo responses of murine granulocytes to human complement-derived, haemolytically inactive C5b67 (iC5b67). Clin Exp Immunol 117:261-8
Tas, S W; Klickstein, L B; Barbashov, S F et al. (1999) C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion. J Immunol 163:5056-63
Mondragon-Palomino, M; Pinero, D; Nicholson-Weller, A et al. (1999) Phylogenetic analysis of the homologous proteins of the terminal complement complex supports the emergence of C6 and C7 followed by C8 and C9. J Mol Evol 49:282-9
Barbashov, S F; Wang, C; Nicholson-Weller, A (1997) Serum amyloid P component forms a stable complex with human C5b6. J Immunol 158:3830-5
Wang, C; Gerard, N P; Nicholson-Weller, A (1996) Signaling by hemolytically inactive C5b67, an agonist of polymorphonuclear leukocytes. J Immunol 156:786-92
Wang, C; Barbashov, S; Jack, R M et al. (1995) Hemolytically inactive C5b67 complex: an agonist of polymorphonuclear leukocytes. Blood 85:2570-8
Benzaquen, L R; Nicholson-Weller, A; Halperin, J A (1994) Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179:985-92
Halperin, J A; Taratuska, A; Rynkiewicz, M et al. (1993) Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood 81:200-5

Showing the most recent 10 out of 31 publications